Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240024/S004

Genio System 2.1

Nyxoah S.A. · Decision date Jul 30, 2026

FDA DECISIONP240024/S004

What did the FDA approve?

FDA records P240024/S004 as a supplement to PMA P240024, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 30, 2026.

FDA approval order statement

Approval for firmware updates to the Activation Chip (AC) Model #2364 of the Genio System 2.1 with associated updates to software documentation, risk management files, and verification and validation reports.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Anesthesiology
Decision date
Jul 30, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P240024/S004
Regulatory pathway
PMA supplement
Applicant
Nyxoah S.A.
Product code
MNQ
Decision code
APPR
Decision date
Jul 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.

Applicant
Nyxoah S.A.
Product code
MNQ
FDA device class
3

For the original device and its historical approval scope, see PMA P240024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240024 · Original PMA

    Genio System 2.1

  2. P240024/S004 received

    Application receipt date recorded by FDA.

  3. P240024/S004 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240024

Product / regulatory recordCompanyPathwayDecision dateSource
Nyxoah S.A.PMA approvalAug 8, 2025FDA
Genio System 2.1P240024/S001
Nyxoah S.A.PMA supplementOct 3, 2025FDA
Genio System 2.1P240024/S002
Nyxoah S.A.PMA supplementNov 6, 2025FDA
Genio System 2.1P240024/S003
Nyxoah S.A.PMA supplementJun 8, 2026FDA

Explore the linked device profile

Other records with product code MNQ

Product / regulatory recordCompanyPathwayDecision dateSource
Inspire Medical SystemsPMA supplementNov 5, 2026FDA
Inspire Medical SystemsPMA supplementOct 26, 2026FDA
Model 3150 IPGP130008/S147
Inspire Medical SystemsPMA supplementOct 22, 2026FDA
Model 3150 IPGP130008/S146
Inspire Medical SystemsPMA supplementOct 13, 2026FDA
Inspire Medical SystemsPMA supplementAug 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Nyxoah S.A.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records